Your patient lost 30 pounds on a GLP-1 and their A1C dropped. So they're healthier, right? Not necessarily. Richard Fleming, a preventive cardiologist who has spent four decades studying surrogate markers in cardiology, argues that weight loss alone tells you almost nothing about whether the patient is actually getting better, and that the bathroom scale has been quietly misleading clinicians and patients on Ozempic, Wegovy, and Mounjaro.

⏱️ Chapters:
0:00 Introduction
1:07 Why 90 percent of what doctors learn turns out to be wrong
1:53 Why the scale lies, and why A1C and LDL lie with it
2:47 The cardiology trials where lowering the number killed patients
4:54 Why the reimbursement system rewards chasing surrogates
6:09 What clinicians should measure instead of weight
7:53 The false sense of security weight loss creates
9:03 The five inflammatory tests every prescriber should run
12:16 The bathroom scale line every prescriber needs to hear
12:32 Where the real GLP-1 benefit may actually be hiding
15:06 What precision medicine actually requires
16:55 Take home messages

About this episode:
Richard Fleming, a preventive cardiologist with a physics and law background who has spent 45 years on inflammatory cardiovascular disease, argues that medicine has built its entire GLP-1 conversation on the wrong endpoint. Surrogate markers like weight, A1C, and LDL are population-level statistics, he says, not individual disease markers, and treating the surrogate as the disease has produced repeated cardiology disasters from the CAST trial to ACCORD to the Women's Health Initiative. Applied to GLP-1 agonists, that means a patient who loses 30 pounds on Ozempic but whose inflammatory, thrombotic, and immunologic markers remain elevated has not actually gotten healthier. Fleming walks through which tests primary care physicians can run before and during GLP-1 therapy, from high-sensitivity CRP to homocysteine to fibrinogen to TNF-alpha to NF-kappa-beta, and explains why the most under-recognized benefit of GLP-1 drugs may be their pleiotropic anti-inflammatory effects, not the weight loss itself. He uses a dam analogy to explain why surrogate markers always catch disease too late, after the damage is done at the tissue level. The conversation lands on a sharper claim than the obesity discourse usually allows: that prescribing a GLP-1 and watching the scale drop, without measuring whether the underlying inflammatory disease is actually improving, leaves the clinician treating the chart rather than the patient. Fleming closes with a reframing of precision medicine as precision measurement, and a challenge to clinicians who reach for surrogates because the billing codes reward it.

🤝 Partner with me on the KevinMD platform:
With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Let's work together to tell your story.

➡️ PARTNER WITH KEVINMD: https://kevinmd.com/influencer
➡️ SUBSCRIBE TO THE PODCAST: https://www.kevinmd.com/podcast
➡️ RECOMMENDED BY KEVINMD: https://www.kevinmd.com/recommended

#GLP1 #PreventiveCardiology #PrimaryCare